{'fraction_non_alphanumeric': 0.01565217391304348, 'fraction_numerical': 0.008695652173913044, 'mean_word_length': 5.776470588235294, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Study of tolcapone for alcohol use shows genetic link to outcome

Patients with alcohol use disorder (AUD) who were genetically predisposed to increased dopamine inactivation in the prefrontal cortex experienced reduced alcohol use with the medication tolcapone, a placebo‐controlled trial has found. The results suggest that inhibition of the enzyme mainly responsible for cortical dopamine inactivation might serve as a promising pharmacological target in the treatment of some patients with AUD. Study results were published online May 6, 2022, in Neuropsychopharmacology.